Tradipitant in the Treatment of Motion Sickness: A Randomized, Double-Blind, Placebo-Controlled Study

Introduction: Novel therapies are needed for the treatment of motion sickness given the inadequate relief and bothersome and dangerous adverse effects of currently approved therapies. Neurokinin-1 (NK1) receptor antagonists have the potential to be effective in improving the symptoms of motion sickn...

Descripción completa

Detalles Bibliográficos
Autores principales: Polymeropoulos, Vasilios M., Czeisler, Mark É., Gibson, Mary M., Anderson, Austin A., Miglo, Jane, Wang, Jingyuan, Xiao, Changfu, Polymeropoulos, Christos M., Birznieks, Gunther, Polymeropoulos, Mihael H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7550735/
https://www.ncbi.nlm.nih.gov/pubmed/33117260
http://dx.doi.org/10.3389/fneur.2020.563373

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7550735/
https://www.ncbi.nlm.nih.gov/pubmed/33117260
http://dx.doi.org/10.3389/fneur.2020.563373

Ejemplares similares